A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥2 Years to <12 Years of Age With Uncontrolled Chronic Spontaneous Urticaria (CSU) (LIBERTY-CSU CUPIDKids)

Who can take part

• Participant must be ≥ 2 years to <12 years of age, at the time of signing the informed consent
• Participants who had history of a diagnosis of CSU prior to screening (Visit 1) or symptoms consistent with a diagnosis of CSU for at least 3 months in the Investigator's opinion
• Participants with CSU (characterized by recurrent itchy wheals with or without angioedema for >6 weeks) who remain symptomatic at the time of screening despite regular H1-antihistamine treatment
• Body weight within ≥5 kg to <60 kg
• Participant/parent(s)/caregiver(s)/participant's legally authorized representative, as appropriate, willing and able to comply with study visits and related procedures

Who cannot take part

• Severe concomitant illness(es) that, in the Investigator's judgment, would adversely affect the participant's participation in the study
• Active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, or antifungals within 2 weeks before the screening visit or during the screening period
• Participation in prior dupilumab clinical study or have been treated with commercially available dupilumab; The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial
• Participants with active tuberculosis (TB) or non-tuberculous mycobacterial infection, or a history of incompletely treated
• Diagnosed with, suspected of, or at high risk of endoparasitic infection
• Active malignancy or history of malignancy within 5 years before the baseline visit
• History of systemic hypersensitivity or anaphylaxis to dupilumab including any excipient
• Participants were excluded from the study if any of the following criteria apply:
• Underlying etiology for chronic urticarias other than CSU
• Presence of skin morbidities other than CSU that may interfere with the assessment of the study outcomes
• Participants with a diagnosis of chronic inducible cold urticaria
• Participants with active AD
• Known or suspected immunodeficiency